Mycosis Fungoides and Sézary Syndrome: Microenvironment and Cancer Progression.
暂无分享,去创建一个
[1] Ruoyan Li,et al. Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment , 2023, JCI insight.
[2] A. Elsensohn,et al. Cutaneous T‐cell lymphoma following dupilumab use: a systematic review , 2022, International journal of dermatology.
[3] D. Weisenburger,et al. Expression of immune checkpoint molecules programmed death protein 1, programmed death‐ligand 1 and inducible T‐cell co‐stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome , 2022, The British Journal of Dermatology.
[4] Robert W. Hsieh,et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. , 2022, The Lancet. Oncology.
[5] U. Wehkamp,et al. The Skin Microbiome and Influencing Elements in Cutaneous T-Cell Lymphomas , 2022, Cancers.
[6] R. Clark,et al. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas , 2022, Blood advances.
[7] J. Dang,et al. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced suppression. , 2022, Blood.
[8] L. Biard,et al. Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome * , 2022, The British journal of dermatology.
[9] P. de la Grange,et al. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing and disease control in mogamulizumab-treated CTCL patients. , 2021, Blood.
[10] M. Khodadoust,et al. Resistance to Mogamulizumab Is Associated with Loss of CCR4 in Cutaneous T Cell Lymphoma , 2021, Blood.
[11] Jie Liu,et al. The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome , 2021, Annals of Dermatology.
[12] L. Michel,et al. Exploring the role of the skin microenvironment in cutaneous T-cell lymphoma using single cell RNA-sequencing. , 2021, European journal of cancer.
[13] J. Scarisbrick,et al. Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). , 2021, European journal of cancer.
[14] A. Pileri,et al. The Microenvironment’s Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications , 2021, Cells.
[15] G. Nolan,et al. Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging , 2021, Frontiers in Immunology.
[16] N. Siemers,et al. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models , 2021, Cancer Research.
[17] F. Tacke,et al. Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy , 2021, Journal for ImmunoTherapy of Cancer.
[18] Salil S. Bhate,et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma , 2020, Nature Communications.
[19] N. Wald,et al. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies , 2020, Molecular Cancer Therapeutics.
[20] Sonali M. Smith,et al. A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930) , 2020 .
[21] J. Scarisbrick,et al. Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome. , 2020, The Journal of investigative dermatology.
[22] P. Gaulard,et al. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. , 2020, Blood advances.
[23] A. Semesi,et al. Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies , 2020, Nature Communications.
[24] T. Krejsgaard,et al. Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma , 2020, Frontiers in Cell and Developmental Biology.
[25] Ellen J. Kim,et al. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. , 2020, Cutis.
[26] M. Bagot,et al. Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas , 2020, Acta dermato-venereologica.
[27] Hyun Je Kim,et al. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. , 2020, The Journal of allergy and clinical immunology.
[28] C. Solinas,et al. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy , 2020, ESMO Open.
[29] H. Kohrt,et al. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] B. Seliger. Basis of PD1/PD-L1 Therapies , 2019, Journal of clinical medicine.
[31] Xiwei Wu,et al. Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile , 2019, Blood.
[32] S. Ogino,et al. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis , 2019, Cancers.
[33] M. Sugaya,et al. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome. , 2019, Acta dermato-venereologica.
[34] J. Conway,et al. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors , 2019, Clinical Cancer Research.
[35] Z. Zeng,et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.
[36] L. French,et al. Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome , 2019, Leukemia & lymphoma.
[37] R. Clark,et al. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. , 2019, JCI insight.
[38] C. Querfeld,et al. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience , 2018, Current opinion in oncology.
[39] C. Elmets,et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.
[40] R. Sun,et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.
[41] A. Halpern,et al. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile , 2018, Cancer Immunology Research.
[42] K. Fujii. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma , 2018, Front. Oncol..
[43] Y. Asano,et al. Interleukin‐25 is involved in cutaneous T‐cell lymphoma progression by establishing a T helper 2‐dominant microenvironment , 2018, The British journal of dermatology.
[44] R. Clark,et al. High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides , 2018, Science Translational Medicine.
[45] Simon C Watkins,et al. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome , 2018, Cancer Immunology, Immunotherapy.
[46] R. Salgia,et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.
[47] Y. Asano,et al. Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome , 2018, The Journal of dermatology.
[48] A. Toubert,et al. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity. , 2017, Blood.
[49] Miao Xu,et al. IL‐25 in allergic inflammation , 2017, Immunological reviews.
[50] W. Dougall,et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy , 2017, Immunological reviews.
[51] J. Szepietowski,et al. Podoplanin Expression Correlates with Disease Progression in Mycosis Fungoides. , 2017, Acta dermato-venereologica.
[52] F. Trautinger,et al. Mast Cells Are Abundant in Primary Cutaneous T-Cell Lymphomas: Results from a Computer-Aided Quantitative Immunohistological Study , 2016, PloS one.
[53] Shinichi Sato,et al. Thymic Stromal Chemokine TSLP Acts through Th2 Cytokine Production to Induce Cutaneous T-cell Lymphoma. , 2016, Cancer research.
[54] N. Mongan,et al. Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover , 2016, Seminars in Immunopathology.
[55] M. Millenson,et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] J. Szepietowski,et al. Expression of CD31 in Mycosis Fungoides. , 2016, Anticancer research.
[57] U. Wehkamp,et al. Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets , 2016, BioMed research international.
[58] Jedd D. Wolchok,et al. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.
[59] C. Assaf,et al. Mac attack: macrophages as key drivers of cutaneous T‐cell lymphoma pathogenesis , 2016, Experimental dermatology.
[60] S. Aiba,et al. The possible interaction between periostin expressed by cancer stroma and tumor‐associated macrophages in developing mycosis fungoides , 2016, Experimental dermatology.
[61] C. Querfeld,et al. Tumor microenvironment in mycosis fungoides and Sézary syndrome , 2016, Current opinion in oncology.
[62] R. Johnston,et al. The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses , 2015, Oncoimmunology.
[63] C. M. Eischen,et al. Genetic markers associated with progression in early mycosis fungoides , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[64] Ji-Hye Park,et al. Expression of Follicular Helper T-cell Markers in Primary Cutaneous T-cell Lymphoma , 2014, The American Journal of dermatopathology.
[65] P. Greenberg,et al. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. , 2014, Trends in immunology.
[66] R. Clark,et al. TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-cell Lymphoma , 2013, Clinical Cancer Research.
[67] J. Becker,et al. Vascular endothelial growth factor receptor-3 expression in mycosis fungoides , 2013, Leukemia & lymphoma.
[68] R. Willemze,et al. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides. , 2012, Archives of dermatology.
[69] Y. Tada,et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. , 2012, Journal of dermatological science.
[70] R. Büttner,et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. , 2012, Blood.
[71] M. Wasik,et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. , 2012, The American Journal of dermatopathology.
[72] R. Clark,et al. Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients , 2012, Science Translational Medicine.
[73] Y. Tada,et al. IL-22, but Not IL-17, Dominant Environment in Cutaneous T-cell Lymphoma , 2011, Clinical Cancer Research.
[74] Katherine G. Evans,et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. , 2010, Archives of dermatology.
[75] H. Rasheed,et al. Immunohistochemical Study of the Expression of Matrix Metalloproteinase-9 in Skin Lesions of Mycosis Fungoides , 2010, The American Journal of dermatopathology.
[76] James J. Campbell,et al. Cutting Edge: Chemokine Receptor CCR4 Is Necessary for Antigen-Driven Cutaneous Accumulation of CD4 T Cells under Physiological Conditions1 , 2007, The Journal of Immunology.
[77] Juan F. García,et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. , 2003, Blood.
[78] M. G. Lewis,et al. Target Role of Langerhans Cells in Mycosis Fungoides: Transmission and Immuno‐Electron Microscopic Studies , 1979, Journal of cutaneous pathology.